reports
Moody's Ratings assigns A2 rating to Pfizer's subsidiary notes offerin...
Moody's Ratings ("Moody's") assigned a A2 rating to the proposed euro-denominated senior unsecured notes offering by Pfizer Netherlands International Finance B.V. (PNIF BV), a wholly-owned subsidiary of Pfizer Inc. (Pfizer). We also assigned a stable outlook to PNIF BV. The A2 rating assigned to P...
- Dominic Rose
- Naresh Chouhan
MFN Drug Pricing - Impact and Implementation (Thematic, 5pgs)
Ahead of today’s signing of an Executive Order to introduce a Most Favoured Nation approach to drug pricing in the US, we show that net pricing in the EU is c.50% lower than in the US & which companies have most to lose from MFN. We also show that, in reality,
- Research Team ACF
ACF Thematic Oncology Lung Cancer Cough LCC 25042025
Lung Cancer Cough (LCC) is an under-served, perhaps unserved therapeutic subsegment of the Lung Cancer/Oncology market. 57-65% of early diagnosis lung cancer patients suffer from LCC, it is a highly debilitating condition. The US lung cancer therapeutics market consensus values range from ~USD 29.9bn in 2023 to ~USD 71.3bn in 2034, suggesting a compound annual growth rate (CAGR) of 8.2% over our 10 year forecast period. LCC is a prevalent symptom among lung cancer patients, and its management is...
- Dominic Rose
- Naresh Chouhan
US Tariffs - Broad Tariffs are Highly Unlikely (7pgs)
Following a number of recent events, we discuss in this note what we think is the most likely outcome for the Pharma industry. We show that broad based tariffs on drugs are highly unlikely, that even if it were to happen, the impact of a 20% tariff is
- Pelham Smithers
- Dominic Rose
- Naresh Chouhan
US Tariffs - Transfer Pricing Could Negate Impact (6pgs)
We show that Big Pharma would not have to shift a single element of supply chain to the US and can mitigate most, if not all, of a 20% tariff on drugs, just by changing their transfer pricing strategy. In a scenario where the US corporation tax rate falls to 15% but tariffs are 20%, we show that Big Pharma profits would be unchanged, while the US government tax take would more than double. The losers would be low tax jurisdictions like Ireland, but they would get to keep their manufacturing base...
GSK: 10 directors
Ten Directors at GSK bought 10,924 shares at between 15.143USD and 15.145USD. The significance rating of the trade was 55/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two y...
Pfizer Invites Public to View and Listen to Webcast of April 29 Confer...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. Participants are advised to re...
- Dominic Rose
- Naresh Chouhan
EU Pharma - 5 Reasons for Further Re-rating (Thematic, 42pgs)
Given the macro backdrop & our evidence in this note that Pharma can sustain faster than expected growth for the next decade, we believe investors should add to their Pharma positions. 2025 is the biggest year for pipeline readouts in recent history and we expect this to catalyse a re-rating. We show that 1) Pipelines are very robust, 2) The market underestimates the size of the “monster” blockbusters that account for 14% of all drugs, 3) 15% of 2030 sales are “generic resistant” due to the moda...
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Hea...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 10:30 a.m. Eastern Standard Time. To listen to the webcast, visit our web site at . Information on accessing and registering for the webcast will be available at beginning today. The transcript and webcast replay of the discussion will be made available on our web site at within 24 hours after the end of the live discussion a...
- Jonathan Moreland
WYNN WYNN RESORTS LIMITED
TTSH TILE SHOP HOLDINGS INC.
OXBR OXBRIDGE RE HOLDINGS
NGL NGL ENERGY PARTNERS LP
HMC HARMONIC
HII HUNTINGTON INGALLS INDUSTRIES INC.
EL ESTEE LAUDER COMPANIES INC. CLASS A
CVS CVS HEALTH CORPORATION
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
BZH BEAZER HOMES USA INC.
BMY BRISTOL-MYERS SQUIBB COMPANY
ASYS AMTECH SYSTEMS INC.
ARCC ARES CAPITAL CORPORATION
AIG AMERICAN INTERNATIONAL GROUP INC.
MDU MDU RESOURCES GROUP INC
CMCO COLUMBUS MCKINNON CORPORATION
USFD US FOODS HOLDING CORP.
FRD FRIEDMAN INDUSTRIES INC.
PLBC PLUMAS BANCORP
FBK FB FINANCIAL CORPORATION
MRUS MERUS B V
PFE PFIZER INC.
XFLT XAI OCTAGON FLOATING RATE ALTERNATIVE INCOME TERM TRUST
RCUS ARCUS BIOSCIENCES
NWPP NEW PEOPLES BANKSHARES INC.
EAF GRAFTECH INTERNATIONAL
AMCR AMCOR PLC
BFC BANK FIRST NATIONAL CORP
CBKM CONSUMERS BANCORP INC.
IDYA IDEAYA BIOSCIENCES
RZLT REZOLUTE
REYN INC.
MTCH REYNOLDS CONSUMER PRODUCTS INC.
ESOA MATCH GROUP INC.
ATAI ENERGY SERVICES OF AMERICA CORP.
FLNC ATAI LIFE SCIENCES BV
BST FLUENCE ENERGY INC
PCT BLACKROCK SCIENCE AND TECHNOLOGY TRUST
CMPO PURECYCLE TECHNOLOGIES INC
EFSI COMPOSECURE INC
LSMG EAGLE FINANCIAL SERVICES INC
SLDB LODE STAR MINING INC
RCEL SOLID BIOSCIENCES INC
MNR AVITA MEDICAL INC
OCX MACH NATURAL RESOURCES LP
FDBC ONCOCYTE CORPORATION
FIDELITY D & D BANCORP INC
Pfizer Inc: 1 director
Two Directors at Pfizer Inc sold/bought 19,764 shares at between 0.000USD and 25.650USD. The significance rating of the trade was 98/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the...
- Jonathan Moreland
XNCR XENCOR INC.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
MKL MARKEL CORPORATION
JBLU JETBLUE AIRWAYS CORPORATION
HMC HARMONIC
HII HUNTINGTON INGALLS INDUSTRIES INC.
EL ESTEE LAUDER COMPANIES INC. CLASS A
BZH BEAZER HOMES USA INC.
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ARCC ARES CAPITAL CORPORATION
CBFV CB FINANCIAL SERVICES INC.
MDU MDU RESOURCES GROUP INC
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
CMCO COLUMBUS MCKINNON CORPORATION
HP HELMERICH & PAYNE INC.
FRD FRIEDMAN INDUSTRIES INC.
HI HILLENBRAND INC.
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
FBK FB FINANCIAL CORPORATION
KALV KALVISTA PHARMACEUTICALS
PFE PFIZER INC.
MPB MID PENN BANCORP INC.
NWPP NEW PEOPLES BANKSHARES INC.
EAF GRAFTECH INTERNATIONAL
NWFL NORWOOD FINANCIAL CORP.
FRAF FRANKLIN FINANCIAL SERVICES CO.
AMCR AMCOR PLC
MFON MOBIVITY HOLDINGS CORP.
PLCE THE CHILDREN'S PLACE RETAIL STORES
ALLY INC.
REYN GMAC LLC
MTCH REYNOLDS CONSUMER PRODUCTS INC.
IMNM MATCH GROUP INC.
CTOS IMMUNOME
FLNC CUSTOM TRUCK ONE SOURCE
PCT INC.
CMPO FLUENCE ENERGY INC
EFSI PURECYCLE TECHNOLOGIES INC
VGAS COMPOSECURE INC
TKO EAGLE FINANCIAL SERVICES INC
MNR VERDE CLEAN FUELS INC
BHRB TKO GROUP HOLDINGS
OCX INC.
SUNS MACH NATURAL RESOURCES LP
BURKE HERBERT FINANCIAL SERVICES CORP
ONCOCYTE CORPORATION
SUNRISE REALTY TRUST
- Jonathan Moreland
BZH BEAZER HOMES USA INC.
CMCO COLUMBUS MCKINNON CORPORATION
FBK FB FINANCIAL CORPORATION
KALV KALVISTA PHARMACEUTICALS
PFE PFIZER INC.
MPB MID PENN BANCORP INC.
AMCR AMCOR PLC
RVLV REVOLVE GROUP
PFX PHENIXFIN CORP
FLNC FLUENCE ENERGY INC
CMPO COMPOSECURE INC
ECBK ECB BANCORP INC.
BHRB BURKE HERBERT FINANCIAL SERVICES CORP
Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival Outco...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced positive results from the Phase 3 TALAPRO-2 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), demonstrating a statistically significant and clinically meaningful improvement in overall survival (OS) compared to placebo plus XTANDI in patients with metastatic castration-resistant prostate cancer (mCRPC), with or without homologous recombination repair (HRR) gene mutations. The TALAPRO-2 results will be presented ...
U.S. FDA Approves Pfizer’s ADCETRIS® Combination Regimen for the treat...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for ADCETRIS® (brentuximab vedotin) in combination with lenalidomide and a rituximab product for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for autologous hemat...
Pfizer and Astellas’ PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® ...
NEW YORK & TOKYO--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) today announced additional follow-up results from the Phase 3 EV-302 clinical trial (also known as KEYNOTE-A39) evaluating the efficacy and safety of PADCEV ® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, plus KEYTRUDA® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). The results showed a sustained overall survival (OS) and progression-free survi...
Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidan...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2024 and reaffirmed its 2025 financial guidance(5) provided on December 17, 2024. The fourth-quarter 2024 earnings presentation and accompanying prepared remarks from management as well as the quarterly update to Pfizer’s R&D pipeline can be found at . EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and financial commitments, strengthen...
Pfizer’s BRAFTOVI® Combination Regimen Significantly Improved Progress...
NEW YORK--(BUSINESS WIRE)-- (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) in patients with metastatic colorectal cancer (mCRC) harboring a BRAF V600E mutation. The trial showed a statistically significant and clinically meaningful improvement in PFS, one of its dual primary endpoints, as assessed by blinded independent central review (BICR) compared to patients receiving ...
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO G...
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium taking place February 13-15 in San Francisco, California. Data from more than 20 company-sponsored, investigator-sponsored, and collaborative research abstracts, including five oral presentations, highlight advancements in developing new standards of care within prostate and bladder cancer across the company’s core scientific modalities, including small molecules and antibody-drug...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.